Teva Pharmaceutical Industries (TEVJF) Share-based Compensation (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Share-based Compensation across 10 years of filings, most recently posting $43.0 million for Q1 2026.

• Quarterly Share-based Compensation rose 26.47% year-over-year to $43.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.0 million (up 28.68% YoY) and the FY2025 annual result came in at $157.0 million, up 27.64% from the prior year.
• Share-based Compensation eased to $43.0 million in Q1 2026, from $51.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $51.0 million in Q4 2025 and troughed at $24.0 million in Q1 2022.
• A 5-year average of $33.5 million and a median of $32.0 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation slipped 23.08% — and 2025, when it jumped 50.0%.
• Tracing TEVJF's Share-based Compensation over 5 years: stood at $36.0 million in 2022, then dropped by 22.22% to $28.0 million in 2023, then advanced by 21.43% to $34.0 million in 2024, then soared by 50.0% to $51.0 million in 2025, then slipped by 15.69% to $43.0 million in 2026.
• Business Quant data shows TEVJF's Share-based Compensation at $43.0 million in Q1 2026, $51.0 million in Q4 2025, and $34.0 million in Q3 2025.